EGFR-IN-33

EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13)[1].

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[1]. Yihan Wang, et al. Substituted acrylamide derivatives and compositions thereof and their uses. Patent WO2021185348A1.